A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is application/pdf
.
Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis
2011
Clinical Medicine Insights: Therapeutics
and purpose: Mitoxantrone (MX) (Novantrone ® ) is approved in Canada for certain refractory cancers and acute nonlymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate the efficacy, safety, and tolerability of MX in SPMS. Experimental approach: A single-centre, open-label, non-randomized study was conducted in patients with a $6 month history of SPMS. The primary parameters
doi:10.4137/cmt.s7586
fatcat:rzt6tbuvmbe6jc4hswkagczxne